Transplant Immunology

📋 Key Information Summary

📋

Human leukocyte antigen (HLA) matching at HLA-A, HLA-B, and HLA-DR loci reduces rejection risk; a six-antigen (0-mismatch) match confers the best long-term graft survival in renal transplantation.
HLA typing is performed by molecular (PCR-SSO/NGS) methods in Australian transplant centres; crossmatching uses complement-dependent cytotoxicity (CDC) and flow cytometry.
Hyperacute rejection occurs within minutes to hours due to pre-formed anti-donor antibodies (anti-HLA or ABO); it is irreversible and mandates immediate graft removal.
Acute cellular rejection (ACR) typically occurs within days to 6 months post-transplant; diagnosed by biopsy (Banff grading); treated with pulsed IV methylprednisolone.
Acute antibody-mediated rejection (AMR) is driven by donor-specific antibodies (DSA); treated with plasma exchange, IV immunoglobulin (IVIG), and rituximab.
Chronic allograft dysfunction manifests months to years post-transplant; involves interstitial fibrosis, tubular atrophy (IF/TA), and transplant glomerulopathy.
Graft-vs-host disease (GVHD) is a risk after allogeneic haematopoietic stem cell transplantation (HSCT); skin, liver, and gut are the primary target organs.
First-line maintenance immunosuppression in solid-organ transplantation is a calcineurin inhibitor (tacrolimus) + mycophenolate mofetil ± corticosteroids.
Tacrolimus trough targets: kidney 5–8 ng/mL (maintenance), liver 5–10 ng/mL, heart 8–12 ng/mL; therapeutic drug monitoring (TDM) is mandatory.
Induction therapy with basiliximab (anti-CD25) is PBS-listed for renal transplant; anti-thymocyte globulin (ATG) is used for high-immunological-risk recipients.
Australia performed 1,482 organ transplants in 2023 (AIHW); organ donation rates remain below international benchmarks, increasing reliance on marginal and extended-criteria donors.
Aboriginal and Torres Strait Islander peoples have higher rates of end-stage kidney disease but lower access to transplant waitlists — equity strategies are essential.

Introduction & Australian Epidemiology

Transplant immunology encompasses the immunological mechanisms governing the acceptance or rejection of transplanted organs, tissues, and cells. The field integrates histocompatibility science, innate and adaptive immune biology, and pharmacological immunosuppression to achieve durable graft function while minimising infection and malignancy risk.

In Australia, organ transplantation is coordinated through the Organ and Tissue Authority (OTA) and Donate Life, with clinical activity concentrated in designated transplant centres across each state and territory. In 2023, Australia recorded 1,482 organ transplant procedures from 503 deceased donors, alongside living-donor programmes (principally renal and liver). Despite national reforms, the deceased organ donation rate of approximately 22 donors per million population (dpmp) remains below leading nations such as Spain (49 dpmp) and the United States (45 dpmp).

Kidney transplantation is the most common procedure (~1,000/year), followed by liver (~250), lung (~200), heart (~150), and pancreas/islet (~50). Allogeneic haematopoietic stem cell transplantation (HSCT) adds approximately 700 procedures annually for malignant and non-malignant haematological conditions. Long-term graft survival has improved markedly over the past two decades, with 5-year deceased-donor kidney graft survival now exceeding 85%, attributable to refined HLA matching, improved immunosuppression, and protocol biopsy surveillance.

Key challenges in the Australian context include geographic barriers to transplantation for rural and remote populations, inequitable access for Aboriginal and Torres Strait Islander peoples, increasing donor age and comorbidity (expanded-criteria donors), and the lifelong burden of immunosuppression-related complications including infection, cardiovascular disease, diabetes, and post-transplant malignancy.

MHC / HLA Matching

The human major histocompatibility complex (MHC), termed the human leukocyte antigen (HLA) system, is located on chromosome 6p21.3 and encodes the most polymorphic genes in the human genome. HLA matching between donor and recipient is a cornerstone of pre-transplant immunological assessment and directly influences graft survival, particularly in renal transplantation.

HLA Classes and Transplant Relevance

Feature	Class I (HLA-A, -B, -C)	Class II (HLA-DR, -DQ, -DP)
Expression	All nucleated cells	Antigen-presenting cells (B cells, macrophages, dendritic cells); upregulated on endothelium during inflammation
Present to	CD8⁺ cytotoxic T cells	CD4⁺ helper T cells
Transplant matching loci	HLA-A, HLA-B	HLA-DR
Rejection role	Direct allorecognition; CD8-mediated cytotoxicity	Indirect allorecognition; antibody production via T-helper cell activation
Allelic diversity (>25,000 alleles total)	>7,000 (HLA-A), >8,000 (HLA-B)	>2,700 (HLA-DRB1)

Australian Typing and Crossmatching Practice

HLA typing in Australia is performed by National Association of Testing Authorities (NATA)-accredited histocompatibility laboratories, typically using molecular methods:

Low-resolution typing: PCR-sequence-specific priming (PCR-SSP) or sequence-specific oligonucleotide probing (PCR-SSO) — identifies HLA antigen-level (2-digit) specificity.
High-resolution typing: Next-generation sequencing (NGS) — identifies allele-level (4–8 digit) specificity; increasingly used for waitlisted patients and living donors to detect permissible mismatches and avoid immunogenic alleles.
Crossmatch testing: Complement-dependent cytotoxicity (CDC) crossmatch (historical standard) and flow cytometry crossmatch (more sensitive). A positive CDC crossmatch is an absolute contraindication to transplantation in most circumstances due to hyperacute rejection risk.
Virtual crossmatch: Using single-antigen bead (SAB) Luminex assays to characterise the recipient's anti-HLA antibody profile (specificity, MFI titre) — allows prospective crossmatching without a physical sample from the donor when donor HLA type is known.

Matching and Graft Survival

The Australian Kidney Exchange Programme (AKX) facilitates incompatible living-donor pairs and maximises HLA matching. Data from ANZDATA demonstrate the following 5-year deceased-donor kidney graft survival by HLA mismatch:

0-mismatch (000): ~92%
1–3 mismatches: ~87%
4–6 mismatches: ~82%

While perfect matching confers the best outcomes, the extreme polymorphism of HLA means that <15% of deceased-donor transplants in Australia achieve a 0-mismatch. Sensitised recipients (panel reactive antibody [PRA] >80%) face prolonged wait times and are prioritised through the national matching algorithms.

⚠️

Sensitised recipients: Patients with PRA >80% have pre-formed anti-HLA antibodies against the majority of the donor pool. Desensitisation protocols (plasma exchange + IVIG ± rituximab) may be considered but are associated with higher rates of antibody-mediated rejection and inferior graft survival compared to non-sensitised recipients.

Rejection Types

Allograft rejection is classified by temporal onset, immunological mechanism, and histopathological pattern. Accurate classification guides treatment intensity and prognosis.

Hyperacute

Minutes to Hours

Pre-formed anti-donor antibodies (anti-HLA Class I, ABO, endothelial) activate complement and coagulation cascade → endothelial injury, thrombosis, graft necrosis.

Setting: Intra-operative / immediate post-op; graft loss is usually irreversible

Acute

Days to 6 Months

Cellular (T-cell mediated) or antibody-mediated (DSA + complement C4d deposition). Acute cellular rejection (ACR) is the most common type; acute AMR is increasingly recognised and carries worse prognosis.

Setting: Inpatient; treatable with pulse steroids, ATG, plasma exchange, or IVIG

Chronic

Months to Years

Progressive graft fibrosis and vasculopathy driven by both immune (DSA, T-cell) and non-immune (ischaemia-reperfusion, hypertension, CNI toxicity, infection) mechanisms. Leading cause of late graft loss.

Setting: Outpatient; management focuses on optimising immunosuppression and controlling non-immune risk factors

Hyperacute Rejection

Hyperacute rejection is a medical emergency characterised by immediate graft thrombosis due to pre-formed circulating antibodies binding to donor endothelium. Risk factors include positive CDC crossmatch, ABO incompatibility (unless a desensitisation protocol is in place), and high-titre anti-endothelial cell antibodies. The affected organ becomes dusky, mottled, and non-functional within minutes of reperfusion. Treatment is immediate graft nephrectomy (kidney) or explantation. Prevention relies on rigorous pre-transplant crossmatch and ABO verification — a sentinel event if missed (NSQHS Standard 7).

Acute Cellular Rejection (ACR)

ACR is mediated primarily by recipient CD4⁺ and CD8⁺ T cells recognising donor HLA antigens via direct (intact donor MHC on passenger leucocytes) and indirect (recipient APC presenting processed donor peptides) pathways. It is the most common form of acute rejection, occurring in 10–20% of renal transplants within the first year despite modern immunosuppression.

Banff classification (kidney, updated 2019):

Grade	Interstitial Inflammation (i)	Tubulitis (t)	Endothelialitis (v)
Borderline (suspicious)	i0 or i1	t1, t2, or t3	v0
IA	i2 or i3	t2	v0
IB	i2 or i3	t3	v0
IIA	Any i	Any t	v1 (mild-moderate)
IIB	Any i	Any t	v2 (severe)
III	Any i	Any t	v2 + arterial transmural or fibrinoid change

Acute Antibody-Mediated Rejection (AMR)

AMR requires three criteria (Banff 2017): (1) histological evidence of acute tissue injury (microvascular inflammation [g+ptc ≥2], thrombotic microangiopathy, or acute tubular injury); (2) evidence of current/recent antibody interaction with endothelium (C4d positivity in peritubular capillaries or molecular evidence of endothelial injury); (3) presence of donor-specific antibodies (DSA). AMR accounts for 20–30% of acute rejection episodes and is more common in sensitised recipients and ABO-incompatible transplants.

Chronic Rejection

Chronic allograft nephropathy (CAN) — now termed interstitial fibrosis/tubular atrophy (IF/TA) of unknown aetiology — is a clinicopathological entity characterised by progressive decline in graft function, proteinuria, and histological changes including interstitial fibrosis (ci), tubular atrophy (ct), transplant glomerulopathy (cg), and arteriolar hyalinosis (ah). Chronic AMR, defined by transplant glomerulopathy + DSA + C4d, is a major driver of late graft loss. Non-immune contributors include calcineurin inhibitor (CNI) nephrotoxicity, hypertension, recurrent native kidney disease, polyomavirus (BK) nephropathy, and chronic ischaemia.

Graft-versus-Host Disease (GVHD)

GVHD occurs when immunocompetent donor T lymphocytes recognise recipient tissues as foreign and mount an immune attack. It is principally a complication of allogeneic haematopoietic stem cell transplantation (HSCT), but can also occur following solid-organ transplantation (particularly liver and small bowel), blood product transfusion (transfusion-associated GVHD), and haploidentical procedures without adequate T-cell depletion.

Acute GVHD

Acute GVHD typically manifests within 100 days of HSCT and involves a three-step process: (1) tissue damage from conditioning chemoradiotherapy releasing pro-inflammatory cytokines (TNF-α, IL-1); (2) donor T-cell activation by recipient APCs; (3) effector cell-mediated target organ apoptosis. The primary targets are skin, liver, and gastrointestinal tract.

Organ	Stage 1	Stage 2	Stage 3	Stage 4
Skin (% BSA rash)	<25%	25–50%	>50%	Generalised erythroderma with bullae/desquamation
Liver (bilirubin, µmol/L)	34–51	51–102	102–255	>255
Gut (diarrhoea volume, mL/day)	500–1000	1000–1500	>1500	>1500 ± pain/ileus

Chronic GVHD

Chronic GVHD (>100 days post-HSCT) is the leading cause of non-relapse mortality and morbidity in long-term HSCT survivors. It resembles autoimmune connective tissue disease with scleroderma-like skin changes, sicca syndrome, bronchiolitis obliterans syndrome (BOS), and hepatic dysfunction. The NIH 2014 consensus classifies chronic GVHD as classic chronic, overlap syndrome (with acute features), or late acute.

GVHD Prophylaxis and Treatment — Australian Practice

💊

Cyclosporin (Ciclosporin)

Neoral® · Sandimmun® · Calcineurin inhibitor

Prophylaxis dose 3 mg/kg/day IV divided Q12H, switch to PO when tolerating oral intake; target trough 200–300 ng/mL (whole blood)

Renal adjustment Reduce dose if CrCl <30 mL/min or rising creatinine >25% from baseline; monitor closely

PBS status ✔ PBS General Benefit

💊

Methotrexate

Generic · Antimetabolite

Prophylaxis dose (mini-MTX) 15 mg/m² IV Day +1, then 10 mg/m² IV Days +3, +6, +11 post-HSCT

Renal adjustment Avoid if CrCl <30 mL/min; dose reduce 50% if CrCl 30–50 mL/min

PBS status ✔ PBS General Benefit

💊

Methylprednisolone

Solu-Medrol® · Corticosteroid

First-line acute GVHD 2 mg/kg/day IV divided Q6–12H; taper over 4–8 weeks if responding

Steroid-refractory GVHD Second-line: ATG, ruxolitinib (Jakavi®), etanercept, or mycophenolate

PBS status ✔ PBS General Benefit

💊

Ruxolitinib

Jakavi® · JAK1/2 inhibitor

Steroid-refractory acute GVHD 10 mg PO BD; dose reduce to 5 mg BD if platelets <25 × 10⁹/L

PBS status ✘ Authority Required (specialist PBS item for steroid-refractory GVHD)

Immunosuppression Protocols

Modern immunosuppression in solid-organ transplantation follows a three-phase model: induction (peri-operative intensive therapy), maintenance (lifelong combination therapy), and rescue (treatment of acute rejection episodes). The goal is to balance adequate immune suppression to prevent rejection against the risks of infection, malignancy, metabolic complications, and drug toxicity.

Induction Therapy

💊

Basiliximab

Simulect® · Anti-CD25 (IL-2Rα) monoclonal antibody

Dose 20 mg IV on Day 0 (pre-reperfusion) and Day 4

Indication Low-to-moderate immunological risk renal transplant recipients

Paediatric dose <35 kg: 10 mg IV Day 0 + Day 4; ≥35 kg: 20 mg IV Day 0 + Day 4

PBS status ✘ Authority Required (PBS transplant item)

💊

Anti-thymocyte globulin (rabbit)

Thymoglobulin® · rATG · Polyclonal antibody

Dose 1–1.5 mg/kg IV daily for 3–7 days; premedicate with paracetamol, diphenhydramine, and hydrocortisone

Indication High immunological risk (PRA >20%, retransplant, young recipient, donor-specific antibodies); also used as rejection rescue

Adverse effects Cytokine release syndrome, profound lymphopenia (>6 months), CMV reactivation, thrombocytopenia

PBS status ✘ Authority Required

Maintenance Immunosuppression — Standard Triple Therapy

The standard maintenance regimen in Australian renal, liver, and heart transplantation is a calcineurin inhibitor (CNI) + an antiproliferative agent + corticosteroids:

💊

Tacrolimus

Prograf® · Advagraf® · Calcineurin inhibitor

Starting dose 0.1–0.2 mg/kg/day PO divided Q12H (immediate-release) or Q24H (extended-release); start pre-transplant or within 24 hours

Trough targets Kidney: 8–12 ng/mL (months 0–3), 5–8 ng/mL (maintenance); Liver: 8–12 ng/mL early, 5–10 ng/mL late; Heart: 10–15 ng/mL early, 8–12 ng/mL late

Key interactions Increased by azoles, macrolides, grapefruit; decreased by rifampicin, phenytoin, carbamazepine, St John's wort

Renal adjustment No dose change, but nephrotoxicity monitoring essential; trough-guided dosing in CKD

PBS status ✔ PBS General Benefit

💊

Mycophenolate mofetil (MMF)

CellCept® · Myfortic® (enteric-coated mycophenolate sodium)

Adult dose 1 g PO BD (CellCeft) or 720 mg PO BD (Myfortic); adjust for GI intolerance or cytopenias

Paediatric dose 600 mg/m²/day PO divided BD (max 2 g/day)

Renal adjustment No dose adjustment in CKD; avoid if GFR <25 mL/min in some centres (limited data)

PBS status ✔ PBS General Benefit

💊

Prednisolone

Solone® · Predsol® · Corticosteroid

Induction 500 mg–1 g IV methylprednisolone peri-operatively, tapering to oral prednisolone

Maintenance 5–10 mg PO daily; many centres aim for steroid withdrawal at 3–6 months in low-risk renal recipients

PBS status ✔ PBS General Benefit

mTOR Inhibitor-Based Regimens

💊

Sirolimus

Rapamune® · mTOR inhibitor

Dose Loading dose 3–6 mg PO, then 1–3 mg PO daily; target trough 5–12 ng/mL

Role CNI-sparing or CNI-free protocols; reduce nephrotoxicity; anti-tumour properties for post-transplant malignancy risk reduction

Adverse effects Hyperlipidaemia, proteinuria, impaired wound healing (avoid <3 months post-transplant), mouth ulcers, pneumonitis, cytopenias

PBS status ✔ PBS General Benefit

Rejection Rescue Protocols

Rejection Type	First-Line Treatment	Second-Line
Mild ACR (Banff IA–IB)	IV methylprednisolone 500 mg daily × 3 days	rATG 1.5 mg/kg IV × 5–7 days if steroid-resistant
Moderate-severe ACR (Banff IIA–III)	IV methylprednisolone 500 mg–1 g daily × 3 days + consider rATG	rATG if not already given; optimise maintenance immunosuppression
Acute AMR	Plasma exchange × 3–6 sessions + IVIG 2 g/kg (total) + pulse methylprednisolone	Rituximab 375 mg/m² IV × 1; bortezomib (off-label); eculizumab (limited PBS availability)
Chronic AMR	Optimise CNI/MMF; DSA monitoring; treat non-immune factors (BP, proteinuria)	Plasma exchange + IVIG (limited evidence); belatacept conversion (if CNI intolerant, not PBS-listed)

🚨

CNI toxicity — nephrotoxicity: Both tacrolimus and cyclosporin cause chronic nephrotoxicity via afferent arteriolar vasoconstriction and interstitial fibrosis. In non-renal solid-organ transplants (heart, liver, lung), CNI-induced chronic kidney disease is a major long-term complication affecting up to 50% of recipients at 10 years. Monitor serum creatinine and tacrolimus troughs at every clinic visit; consider CNI minimisation or mTOR conversion when eGFR declines.

Investigations

ESSENTIAL

HLA typing (A, B, C, DR, DQ) — molecular

Performed by NATA-accredited histocompatibility laboratories (e.g., NSW Tissue Typing, Qld Health Immunology, Victorian Transplantation & Immunogenetics Service). NGS-based high-resolution typing is gold standard for waitlisting.

ESSENTIAL

Single-antigen bead (SAB) Luminex panel

Identifies anti-HLA antibody specificities and mean fluorescence intensity (MFI); used for virtual crossmatch and monitoring DSA post-transplant.

ESSENTIAL

CDC and flow cytometry crossmatch

CDC crossmatch mandatory pre-transplant; flow cytometry crossmatch more sensitive for low-level anti-HLA antibodies.

AVAILABLE

Graft biopsy — Banff scoring

Protocol (surveillance) and for-cause biopsies; light microscopy, immunofluorescence (C4d), and electron microscopy. Performed at all Australian transplant centres.

AVAILABLE

Donor-derived cell-free DNA (dd-cfDNA)

Emerging non-invasive biomarker of graft injury; AlloMap® and donor-derived cfDNA assays increasingly available in Australian reference laboratories. May reduce biopsy frequency for monitoring.

AVAILABLE

Therapeutic drug monitoring (TDM) — trough levels

Tacrolimus (immunoassay or LC-MS/MS), cyclosporin, sirolimus, everolimus trough levels. MBS item available for transplant-associated TDM.

AVAILABLE

BK virus (BKV) quantitative PCR

Monitor plasma BKV DNA monthly for first 3–6 months post-kidney transplant, then 3-monthly; >10,000 copies/mL warrants CNI/MMF reduction.

REFERRAL

Mixed lymphocyte reaction (MLR) / T-cell ELISPOT

Research/large-centre setting; measures alloreactive T-cell responses for risk stratification; not routinely available.

Special Populations

🤰 Pregnancy

Tacrolimus

Compatible; continue in pregnancy. Trough levels may fall due to increased volume of distribution — increase monitoring frequency to fortnightly.

Mycophenolate mofetil

Contraindicated — Category X. Teratogenic (microtia, craniofacial defects). Discontinue ≥6 weeks before conception; substitute azathioprine.

Sirolimus / Everolimus

Contraindicated — Category D. Discontinue ≥12 weeks before planned pregnancy.

Prednisolone

Compatible at low doses (<20 mg/day). Monitor for gestational diabetes. Foetal adrenal suppression at higher doses.

Azathioprine

Compatible in pregnancy (standard replacement for MMF). TPMT testing before initiation to guide dosing.

👶 Paediatrics

Tacrolimus

Higher mg/kg dosing required (0.15–0.3 mg/kg/day) due to increased clearance. Paediatric trough targets identical to adults. Liquid formulation (Prograf® suspension) available for infants.

MMF

600 mg/m²/day PO divided BD; use suspension formulation in young children.

Basiliximab

Dose: 10 mg IV if <35 kg; 20 mg IV if ≥35 kg. Same schedule (Day 0 + Day 4).

General

Growth monitoring essential (steroid minimisation preferred). Ensure catch-up immunisations pre-transplant; live vaccines contraindicated post-transplant. Paediatric transplant managed at tertiary centres (e.g., The Children's Hospital at Westmead, RCH Melbourne).

👴 Elderly

Immunosuppression strategy

Reduced-intensity protocols increasingly used (e.g., steroid-free + basiliximab induction). Higher infection risk (CMV, PJP, urinary tract). Cancer surveillance critical — post-transplant lymphoproliferative disorder (PTLD) and skin cancer rates increase with cumulative immunosuppression.

Drug interactions

Polypharmacy increases CNI interaction risk. Avoid concurrent nephrotoxins (NSAIDs, aminoglycosides). Fall risk with high-dose corticosteroids.

🫘 Renal Impairment

Tacrolimus

Nephrotoxic — the primary dose-limiting toxicity. In non-renal transplants with declining eGFR, reduce trough targets and consider early mTOR conversion. In renal transplant, CNI nephrotoxicity vs rejection is a key clinical challenge — protocol biopsies help distinguish.

Methotrexate (GVHD prophylaxis)

Avoid if CrCl <30 mL/min; dose reduce 50% for CrCl 30–50. Leucovorin rescue if toxicity occurs.

🫁 Hepatic Impairment

Tacrolimus

Metabolised hepatically (CYP3A4). In liver transplant recipients with graft dysfunction, levels may fluctuate wildly — increase TDM frequency to daily in acute setting.

Mycophenolate

MPA is glucuronidated hepatically; accumulation in severe liver dysfunction. Use cautiously with dose reduction.

🦠 Immunocompromised

Infection prophylaxis (mandatory post-transplant)

PJP: Cotrimoxazole 480 mg PO daily or 960 mg PO 3×/week for 6–12 months. CMV: Valganciclovir prophylaxis (900 mg PO daily) for D+/R− or R+ patients on ATG, for 3–6 months. Fungal: Fluconazole 200 mg PO daily for 1 month (liver transplant). Ensure all vaccinations up to date pre-transplant.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander peoples experience disproportionately high rates of end-stage kidney disease (ESKD) — approximately 7 times the rate of non-Indigenous Australians — driven by higher prevalence of type 2 diabetes, hypertension, and socioeconomic disadvantage. Despite this, Indigenous Australians are underrepresented on transplant waitlists and have lower rates of living-donor transplantation.

Transplant access

Indigenous Australians are less likely to be referred for transplant assessment, less likely to have a potential living donor identified, and face longer wait times. Active equity strategies — including culturally safe transplant assessment clinics and outreach — are essential.

Remote and rural follow-up

Post-transplant follow-up requires regular blood tests (CNI troughs, renal function, FBC) and clinic visits. Patients in remote communities may be >500 km from a transplant centre. Telehealth, fly-in specialist clinics, and partnership with local Aboriginal Medical Services (AMS) are critical. Point-of-care testing for creatinine and tacrolimus troughs may facilitate remote monitoring.

Medication adherence

Lifelong immunosuppression requires strict adherence. Barriers include health literacy, language differences (interpreters essential), complex medication regimens, pharmacy access in remote communities, and cost (even PBS-subsidised medications may be unaffordable without closing-the-gap co-payment programmes). Dose Administration Aids (DAAs) and community pharmacist engagement improve adherence.

Infection risk

Higher baseline rates of communicable diseases (hepatitis B, Strongyloides, rheumatic heart disease) require pre-transplant screening. Post-transplant infection prophylaxis must be culturally appropriate and accessible.

Organ donation

Aboriginal and Torres Strait Islander peoples are underrepresented as organ donors. Community engagement, yarning circles, and culturally appropriate organ donation education programmes (aligned with Donate Life and community Elders) are important to address historical mistrust and increase donation rates.

Monitoring

Post-transplant monitoring integrates graft function surveillance, immunosuppression drug levels, infection screening, and metabolic complication prevention. The frequency and intensity of monitoring is highest in the first 3 months and gradually reduces over the first year.

Week 1–2

Daily: FBC, UEC, LFT, CNI trough level; urine output and fluid balance (renal transplant). Twice-weekly: CMV PCR (if D+/R−). Once: BKV PCR baseline.

Month 1–3

Weekly–fortnightly: Clinic review, UEC, CNI trough, FBC. Monthly: BKV PCR, CMV PCR, fasting lipids, glucose/HbA1c. At 3 months: Protocol biopsy (if centre policy), DSA monitoring.

Month 3–12

Monthly: Clinic review, UEC, CNI trough, FBC, LFT. 3-monthly: BKV PCR, CMV PCR, fasting lipids, HbA1c. 6-monthly: DSA, chest X-ray (lung transplant).

Year 1+

3–6 monthly: Clinic review, UEC, CNI trough, FBC, LFT, lipids, HbA1c, urine PCR. Annual: DSA, BKV PCR, age-appropriate cancer screening (skin, cervical, bowel), bone density (if steroid use >3 months), ophthalmology (cataracts, if steroids).

📚 References

1. Loupy A, Haas M, Roufosse C, et al. The Banff 2019 Kidney Meeting Report: Banff classification of antibody-mediated rejection and chronic active T cell-mediated rejection. Am J Transplant. 2020;20(4):806–819.
2. Transplantation Society of Australia and New Zealand (TSANZ). Clinical guidelines for organ transplantation from deceased donors. Version 2.0. 2021. Available from: https://www.tsanz.com.au
3. Australian Institute of Health and Welfare (AIHW). Australia's organ and tissue donation and transplantation annual report 2023. Canberra: AIHW; 2024.
4. Australian and New Zealand Dialysis and Transplant Registry (ANZDATA). ANZDATA 46th annual report 2023. Adelaide: ANZDATA; 2023. Available from: https://www.anzdata.org.au
5. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2024;14(1):1–163.
6. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.
7. Clayton PA, McDonald SP, Chadban SJ. Steroids and recurrent IgA nephropathy after kidney transplantation. J Am Soc Nephrol. 2011;22(6):1171–1179.
8. Australian Commission on Safety and Quality in Health Care (ACSQHC). National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2021.
9. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation. 2006;81(9):1234–1248.
10. Hoy WE, Mathews JD, McCredie DA, et al. The multidimensional nature of renal disease: rates and associations of albuminuria in an Australian Aboriginal community. Kidney Int. 1998;54(4):1296–1304.
11. Grace JA, Angus PW. Rational prescribing of immunosuppressive drugs in liver transplantation. Aust Prescr. 2019;42(4):118–123.
12. Australian Society of Clinical Immunology and Allergy (ASCIA). Guidelines for the management of transplant immunology. 2023. Available from: https://www.allergy.org.au